Capital World Investors2026-Q1
Capital World Investors' 2026-Q1 13F filing shows the firm actively rebalancing with a sharp increase in energy names and a new health care buy, alongside trimming of tech giants like Microsoft and Broadcom.
| Ticker | Action | Value Change |
|---|---|---|
| AZN | new_buy | a notable change |
| TTE | add | +$4.04B |
| AVGO | trim | -$6.71B |
| SNPS | sold_out | a notable change |
| EOG | add | +$3.24B |
The firm initiated a new buy in AstraZeneca worth $5.52B, a stake that did not exist in the prior period. This addition contributes 0.75% to the portfolio weight, expanding the Health Care allocation, which already stood at 13.21% of assets. Capital World Investors directly added this name to its health care holdings.
Capital World Investors trimmed its Broadcom holding by -$6.71B, dropping the portfolio weight from 5.80% to 4.91%. Despite the reduction, AVGO remains the largest single position at $35.96B. The firm made an active decision to pare back semiconductor exposure.
The fund added significantly to TotalEnergies, boosting its stake from $419.2M to $4.46B, a +$4.04B increase. The weight rose from 0.06% to 0.61%, part of a wider push into Energy that includes similar adds in EOG Resources and XOM. Energy sector allocation climbed to 5.25% of the portfolio.
The fund sold its entire SNPS position, which previously had a value of $3.12B and represented 0.42% of assets. This sold-out action removed that exposure entirely and fits with a pattern of trimming technology holdings, as positions in other chips and software stocks like AVGO and MSFT were also reduced.
Capital World Investors rotated away from megacap technology and into energy and health care during the first quarter. The fund boosted stakes in TotalEnergies and AstraZeneca while trimming Broadcom and Microsoft, reflecting a deliberate rebalancing. Other investors can view this filing as a real-money snapshot of institutional sector preference during the period.